| Trial ID: | L6490 |
| Source ID: | NCT01770483
|
| Associated Drug: |
Nitazoxanide
|
| Title: |
The Role Of Nitazoxanide, Interferon Alfa And Ribavirin In Treatment Of Hepatitis C Infected Type 2 Diabetic Patients
|
| Acronym: |
HEP-C-FM
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01770483/results
|
| Conditions: |
Hepatitis C, Chronic|DIABETES MELLITUS Type 2
|
| Interventions: |
DRUG: nitazoxanide|DRUG: conventional interferon alfa|DRUG: Ribavirin
|
| Outcome Measures: |
Primary: Sustained Viral Response,, Sustained viral response ,is negative Hepatitis C Virus(PCR)RNA test six months after end of treatment., 48 WEEK | Secondary: Normalization of Alanine Transferase Test, Liver function test,showing resolution of the inflammation of liver parenchyma, 48week
|
| Sponsor/Collaborators: |
Sponsor: Services Institute of Medical Sciences, Pakistan | Collaborators: Getz Pharma
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
66
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2011-07
|
| Completion Date: |
2013-03
|
| Results First Posted: |
2013-04-17
|
| Last Update Posted: |
2013-09-20
|
| Locations: |
Endocrinology and Diabetes management centre, Lahore, Punjab, Pakistan
|
| URL: |
https://clinicaltrials.gov/show/NCT01770483
|
